acl6kprq22009results991.htm









Exhibit 99.1
 
 

 
 
Alcon Reports Solid Financial Results for Second Quarter
 


Second Quarter Highlights




·  

Organic sales growth was 3.3 percent in second quarter (-3.4 percent reported)
 




·  

Cost management programs contributed to earnings per share of $1.94
 




·  

Operational leverage continued as earnings per share rose 3.2  percent
 




·  

Management raises full year earnings per share guidance
 


HUENENBERG, Switzerland – July 22, 2009 – Alcon, Inc. (NYSE:ACL) reported global sales of $1,677 million for the second quarter of 2009, a 3.3 percent increase excluding the impact of foreign exchange fluctuations, or a decrease of 3.4 percent compared to the second quarter
of 2008 on a reported basis. Net earnings for the second quarter of 2009 rose 2.6 percent to $582 million, or $1.94 per diluted share, compared to $567 million, or $1.88 per diluted share, in the second quarter of 2008.
“Organic sales growth is coming in as expected in 2009, as we continue to execute our sales and marketing strategies that allow us to grow even in the face of global economic weakness,” said Kevin Buehler, Alcon’s president and chief executive officer. “We expect that further development of key businesses like glaucoma,
advanced technology intraocular lenses and emerging markets will enable us to achieve our full year guidance of mid-single digit organic sales growth with somewhat higher organic growth in the second half of the year than in the first, and to translate that growth into solid earnings performance.”


Sales Highlights
Summarized below are the key drivers of sales in the second quarter of 2009.  All growth comparisons are for the second quarter of 2009 compared to the second quarter of 2008.  Organic sales growth rates exclude currency impacts and acquisitions and are non-GAAP measures that are reconciled in a table at the end of this
release.
 




Ø  

International organic sales growth was 5.9 percent (-6.4 percent reported), with emerging markets rising 8.1 percent organically (-8.2 percent reported).
 




Ø  

U.S. sales stabilized as they increased 0.3 percent due to strong contributions from advanced technology AcrySof® intraocular lenses and share gains and market growth in glaucoma offset by generic
competition to TobraDex® ophthalmic suspension.
 




Ø  

Advanced technology intraocular lenses rose 38.3 percent organically, (+30.1 percent reported) due to market share gains by the AcrySof® ReSTOR® Aspheric
+3.0 lens, which was launched in the United States in January of 2009, and the continued rapid adoption of AcrySof® IQ Toric by cataract surgeons.
 




Ø  

Glaucoma sales rose 16.6 percent organically (+8.3 percent reported) led by a 23.6 percent organic rise (+15.4 percent reported) in global sales of TRAVATAN®,
TRAVATAN Z® and DuoTravTM ophthalmic solutions, as these products continued global market share growth in the prostaglandin category.  The launch of Azarga® ophthalmic
solution in the European Union contributed to unit growth of 15.5 percent for the Azopt®/Azarga® family.
 




Ø  

Sales of allergy products declined 1.8 percent organically (-4.8 percent reported), consistent with the company’s expectations for a weaker spring allergy market in the United States.  The company increased combined Patanol® and Pataday™ ophthalmic
solutions U.S. market share to 78.6 percent May year-to-date, an improvement of 0.8 percent over the prior year.
 
 


 
 
Earnings Highlights
 
 
Summarized below are the key drivers of earnings in the second quarter of 2009.  All growth comparisons are for the second quarter of 2009 compared to the second quarter of 2008.
 
 




Ø  

Operating income margin rose from 37.2 to 37.7 percent of sales and net income margin increased from 32.6 percent to 34.7 percent of sales.
 




Ø  

Cost management programs and foreign exchange fluctuations led to a sharp reduction in selling general and administrative expenses from 30.4 to 27.9 percent of sales.
 




Ø  

Other income in the second quarter of 2009 was $19 million compared to $4 million in the second quarter of 2008, due primarily to gains from foreign currency transactions.
 




Ø  

The effective tax rate for the second quarter of 2009 was 10.6 percent, which included approximately one percentage point of period benefits related to settlement with tax authorities on prior year taxes.


Other Highlights




Ø  

Alcon has entered into a five-year collaborative research agreement with AstraZeneca for the exclusive ophthalmic discovery and potential development rights to AstraZeneca’s compound library.  The agreement covers multiple classes of small molecules with lead compounds targeting development of drugs to treat sight-threatening conditions
such as glaucoma, wet and dry age-related macular degeneration and other retinal diseases, as well as ocular allergy, dry eye and other inflammatory eye conditions.
 




Ø  

Alcon has entered into a research and licensing agreement with PhiloGene, Inc. for rights to a VEGF protein.  The company plans to develop this protein for the treatment of wet age related macular degeneration and diabetic macular edema.
 




Ø  

The company plans to launch TOBRADEX® ST ophthalmic suspension, a new formulation of tobramycin/dexamethasone formulated with the ZexioTM delivery
system that enhances bioavailability to targeted tissues.
 




Ø  

Alcon completed the European Union decentralized registration procedure for Vigamox® ophthalmic solution. National licenses have been
issued by Bulgaria, Iceland and Romania and the company is awaiting licensing from the remaining 23 countries.
 




Ø  

The company filed an NDA supplement requesting approval of Patanase™ nasal spray for use in patients from 6 months to 12 years of age.
 




Ø  

Alcon filed a drug approval application in selected European Union markets for CILODEX® otic suspension for the treatment of middle and outer ear infections.  CILODEX® is
the European trade name for CiproDex® otic suspension marketed in the United States.
 




Ø  

Alcon commenced a Phase 2 clinical trial of the aganocide compound NVC-422 for viral conjunctivitis.  This compound is licensed from NovaBay, Inc.
 




Ø  

Alcon notified its publicly-listed German subsidiary, WaveLight AG, that it plans to acquire the remaining publicly-held WaveLight shares at a price of EUR 20.02 pursuant to German securities law.
 




Ø  

The court vacated the July 27, 2009 trial date that had been scheduled for Alcon’s patent infringement action against Apotex related to Patanol®. The court said a new trial date would be set
by a separate order.
 
 


 
Financial Guidance
The company reaffirmed its previously-issued sales guidance for full year 2009 organic sales growth to be in the mid-single digits.  The company raised its guidance for full year 2009 diluted earnings per share on a U.S. GAAP basis to between $6.20 and $6.35 and between $6.25 and $6.40 on a non-GAAP adjusted basis (excluding
restructuring charges taken in the first half of 2009).  This increase reflects positive earnings performance in the first half of the year, which is expected to be partially mitigated by higher R&D and SG&A expenses in the second half of the year.


About Alcon
Alcon, Inc. is the world’s leading eye care company, with sales of approximately $6.3 billion in 2008.  Alcon, which has been dedicated to the ophthalmic industry for 65 years, researches, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contacts lens solutions and other vision care products
that treat diseases, disorders and other conditions of the eye.  Alcon operates in 75 countries and sells products in 180 markets. Alcon’s majority shareholder is Nestlé, S.A., the world’s largest food company.  For more information on Alcon, Inc., visit the Company’s web site at www.alcon.com.



 



  

  
  

  

ALCON, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Earnings (Unaudited)
(in millions, except share data)





  
 

Three months ended
 
 

Six months ended
 
  
 

June 30,
 
 

June 30,
 
  
 

2009
 
 

2008
 
 

2009
 
 

2008
 
  
 
 
 
 
 
 
 
 
 
 
 
 

Sales
 
$
1,677
 
 
$
1,736
 
 
$
3,170
 
 
$
3,272
 

Cost of goods sold
 
 
415
 
 
 
415
 
 
 
769
 
 
 
813
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Gross profit
 
 
1,262
 
 
 
1,321
 
 
 
2,401
 
 
 
2,459
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Selling, general and administrative
 
 
468
 
 
 
527
 
 
 
940
 
 
 
1,011
 

Research and development
 
 
157
 
 
 
142
 
 
 
303
 
 
 
287
 

Amortization of intangibles
 
 
5
 
 
 
6
 
 
 
12
 
 
 
15
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Operating income
 
 
632
 
 
 
646
 
 
 
1,146
 
 
 
1,146
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Other income (expense):
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Gain (loss) from foreign currency, net
 
 
9
 
 
 
(3 
)
 
 
(1 
)
 
 
3
 

Interest income
 
 
13
 
 
 
20
 
 
 
24
 
 
 
46
 

Interest expense
 
 
(5 
)
 
 
(14 
)
 
 
(10 
)
 
 
(32 
)

Other, net
 
 
2
 
 
 
1
 
 
 
6
 
 
 
(10 
)
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Earnings before income taxes
 
 
651
 
 
 
650
 
 
 
1,165
 
 
 
1,153
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Income taxes
 
 
69
 
 
 
83
 
 
 
131
 
 
 
157
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Net earnings
 
$
582
 
 
$
567
 
 
$
1,034
 
 
$
996
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Basic earnings per common share
 
$
1.95
 
 
$
1.90
 
 
$
3.46
 
 
$
3.34
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Diluted earnings per common share
 
$
1.94
 
 
$
1.88
 
 
$
3.44
 
 
$
3.30
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Basic weighted average common shares
 
 
298,744,287
 
 
 
298,477,807
 
 
 
298,663,437
 
 
 
298,100,370
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Diluted weighted average common shares
 
 
300,638,975
 
 
 
301,986,076
 
 
 
300,328,778
 
 
 
301,558,546
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 





  

  
  

  

ALCON, INC. AND SUBSIDIARIES
Global Sales
(USD in millions)





  

Three Months Ended
  
  
  
  
  

Foreign
  
  
  
  
  
  

June 30,
  
  
  
  
  

Currency
  
  

Organic
  
  
  

2009
  

2008
  
  

Change
  
  

Change
  
  

Change
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Geographic Sales
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Alcon United States:
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Pharmaceutical

$

391
  

$

408
  
  

(4.2

)

%

--
  

%

(4.2

)

%

Surgical
  

296
  
  

276
  
  

7.2
  
  

--
  
  

7.2
  
  

Consumer Eye Care
  

103
  
  

104
  
  

(1.0

)
  

--
  
  

(1.0

)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total United States Sales
  

790
  
  

788
  
  

0.3
  
  

--
  
  

0.3
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Alcon International:
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Pharmaceutical
  

322
  
  

338
  
  

(4.7

)
  

(13.3

)
  

8.6
  
  

Surgical
  

461
  
  

492
  
  

(6.3

)
  

(11.8

)
  

5.5
  
  

Consumer Eye Care
  

104
  
  

118
  
  

(11.9

)
  

(11.9

)
  

--
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total International Sales
  

887
  
  

948
  
  

(6.4

)
  

(12.3

)
  

5.9
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Global Sales

$

1,677
  

$

1,736
  
  

(3.4

)
  

(6.7

)
  

3.3
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Global Product Sales
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Infection/inflammation

$

208
  

$

231
  
  

(10.0

)

%

(6.1

)

%

(3.9

)

%

Glaucoma
  

274
  
  

253
  
  

8.3
  
  

(8.3

)
  

16.6
  
  

Allergy
  

160
  
  

168
  
  

(4.8

)
  

(3.0

)
  

(1.8

)
  

Otic/nasal
  

103
  
  

103
  
  

--
  
  

(1.0

)
  

1.0
  
  

Other pharmaceuticals/rebates
  

(32

)
  

(9

)
  

N/M
  
  

N/M
  
  

N/M
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Pharmaceutical
  

713
  
  

746
  
  

(4.4

)
  

(6.0

)
  

1.6
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Intraocular lenses
  

289
  
  

288
  
  

0.3
  
  

(8.4

)
  

8.7
  
  

Cataract/vitreoretinal
  

440
  
  

449
  
  

(2.0

)
  

(7.1

)
  

5.1
  
  

Refractive
  

28
  
  

31
  
  

(9.7

)
  

(6.5

)
  

(3.2

)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Surgical
  

757
  
  

768
  
  

(1.4

)
  

(7.5

)
  

6.1
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Contact lens disinfectants
  

116
  
  

123
  
  

(5.7

)
  

(3.3

)
  

(2.4

)
  

Artificial tears
  

70
  
  

70
  
  

--
  
  

(10.0

)
  

10.0
  
  

Other
  

21
  
  

29
  
  

(27.6

)
  

(10.4

)
  

(17.2

)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Consumer Eye Care
  

207
  
  

222
  
  

(6.8

)
  

(6.3

)
  

(0.5

)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Global Sales

$

1,677
  

$

1,736
  
  

(3.4

)
  

(6.7

)
  

3.3
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
N/M - Not Meaningful
Note: Organic change calculates sales growth without the impact of foreign exchange fluctuations and acquisitions. Management believes organic sales change is an important measure of the company’s operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local
currency prices.  This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.  Certain reclassifications have been made to prior year amounts to conform to current year presentation.



  

  
  

  

ALCON, INC. AND SUBSIDIARIES
Global Sales
(USD in millions)





  

Six Months Ended
  
  
  
  
  

Foreign
  
  
  
  
  
  

June 30,
  
  
  
  
  

Currency
  
  

Organic
  
  
  

2009
  

2008
  
  

Change
  
  

Change
  
  

Change
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Geographic Sales
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Alcon United States:
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Pharmaceutical

$

698
  

$

726
  
  

(3.9

)

%

--
  

%

(3.9

)

%

Surgical
  

554
  
  

530
  
  

4.5
  
  

--
  
  

4.5
  
  

Consumer Eye Care
  

196
  
  

204
  
  

(3.9

)
  

--
  
  

(3.9

)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total United States Sales
  

1,448
  
  

1,460
  
  

(0.8

)
  

--
  
  

(0.8

)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Alcon International:
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Pharmaceutical
  

641
  
  

648
  
  

(1.1

)
  

(13.1

)
  

12.0
  
  

Surgical
  

876
  
  

936
  
  

(6.4

)
  

(12.7

)
  

6.3
  
  

Consumer Eye Care
  

205
  
  

228
  
  

(10.1

)
  

(13.6

)
  

3.5
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total International Sales
  

1,722
  
  

1,812
  
  

(5.0

)
  

(13.0

)
  

8.0
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Global Sales

$

3,170
  

$

3,272
  
  

(3.1

)
  

(7.2

)
  

4.1
  
  

Global Product Sales
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Infection/inflammation

$

410
  

$

459
  
  

(10.7

)

%

(6.1

)

%

(4.6

)

%

Glaucoma
  

507
  
  

463
  
  

9.5
  
  

(8.6

)
  

18.1
  
  

Allergy
  

303
  
  

299
  
  

1.3
  
  

(1.7

)
  

3.0
  
  

Otic/nasal
  

179
  
  

170
  
  

5.3
  
  

(2.3

)
  

7.6
  
  

Other pharmaceuticals/rebates
  

(60

)
  

(17

)
  

N/M
  
  

N/M
  
  

N/M
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Pharmaceutical
  

1,339
  
  

1,374
  
  

(2.5

)
  

(6.1

)
  

3.6
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Intraocular lenses
  

537
  
  

549
  
  

(2.2

)
  

(8.8

)
  

6.6
  
  

Cataract/vitreoretinal
  

840
  
  

855
  
  

(1.8

)
  

(7.9

)
  

6.1
  
  

Refractive
  

53
  
  

62
  
  

(14.5

)
  

(6.4

)
  

(8.1

)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Surgical
  

1,430
  
  

1,466
  
  

(2.5

)
  

(8.2

)
  

5.7
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Contact lens disinfectants
  

222
  
  

237
  
  

(6.3

)
  

(4.6

)
  

(1.7

)
  

Artificial tears
  

135
  
  

136
  
  

(0.7

)
  

(11.7

)
  

11.0
  
  

Other
  

44
  
  

59
  
  

(25.4

)
  

(6.8

)
  

(18.6

)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Consumer Eye Care
  

401
  
  

432
  
  

(7.2

)
  

(7.2

)
  

--
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Global Sales

$

3,170
  

$

3,272
  
  

(3.1

)
  

(7.2

)
  

4.1
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
N/M - Not Meaningful
Note: Organic change calculates sales growth without the impact of foreign exchange fluctuations and acquisitions. Management believes organic sales change is an important measure of the company’s operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local
currency prices.  This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.  Certain reclassifications have been made to prior year amounts to conform to current year presentation.







  

  
  

  

ALCON, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited)
(in millions, except share data)





  
 

June 30,
 
 

December 31,
 
  
 

2009
 
 

2008
 

Assets
 
 
 
 
 
 

Current assets:
 
 
 
 
 
 

Cash and cash equivalents
 
$
2,260
 
 
$
2,449
 

Short term investments
 
 
426
 
 
 
564
 

Trade receivables, net
 
 
1,319
 
 
 
1,168
 

Inventories
 
 
626
 
 
 
574
 

Deferred income tax assets
 
 
146
 
 
 
221
 

Other current assets
 
 
236
 
 
 
243
 
  
 
 
 
 
 
 
 
 

Total current assets
 
 
5,013
 
 
 
5,219
 
  
 
 
 
 
 
 
 
 

Long term investments
 
 
137
 
 
 
24
 

Property, plant and equipment, net
 
 
1,191
 
 
 
1,138
 

Intangible assets, net
 
 
78
 
 
 
91
 

Goodwill
 
 
645
 
 
 
645
 

Long term deferred income tax assets
 
 
352
 
 
 
342
 

Other assets
 
 
103
 
 
 
92
 
  
 
 
 
 
 
 
 
 

Total assets
 
$
7,519
 
 
$
7,551
 
  
 
 
 
 
 
 
 
 

Liabilities and Shareholders' Equity
 
 
 
 
 
 
 
 

Current liabilities:
 
 
 
 
 
 
 
 

Accounts payable
 
$
217
 
 
$
199
 

Short term borrowings
 
 
883
 
 
 
1,059
 

Current maturities of long term debt
 
 
1
 
 
 
1
 

Other current liabilities
 
 
966
 
 
 
931
 
  
 
 
 
 
 
 
 
 

Total current liabilities
 
 
2,067
 
 
 
2,190
 
  
 
 
 
 
 
 
 
 

Long term debt, net of current maturities
 
 
57
 
 
 
61
 

Long term deferred income tax liabilities
 
 
23
 
 
 
22
 

Other long term liabilities
 
 
592
 
 
 
587
 

Contingencies
 
 
 
 
 
 
 
 

Shareholders' equity:
 
 
 
 
 
 
 
 

Common shares, par value CHF 0.20 per share
 
 
42
 
 
 
42
 

Additional paid-in capital
 
 
1,490
 
 
 
1,449
 

Accumulated other comprehensive income
 
 
139
 
 
 
80
 

Retained earnings
 
 
3,684
 
 
 
3,699
 

Treasury shares, at cost
 
 
(575 
)
 
 
(579 
)
  
 
 
 
 
 
 
 
 

Total shareholders' equity
 
 
4,780
 
 
 
4,691
 
  
 
 
 
 
 
 
 
 

Total liabilities and shareholders' equity
 
$
7,519
 
 
$
7,551
 
  
 
 
 
 
 
 
 
 





  

  
  

  

ALCON, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in millions)





  
 

Six months ended June 30,
 
  
 

2009
 
 

2008
 
  
 
 
 
 
 
 

Cash provided by (used in) operating activities:
 
 
 
 
 
 

Net earnings
 
$
1,034
 
 
$
996
 

Adjustments to reconcile net earnings to cash provided from
 
 
 
 
 
 
 
 

operating activities:
 
 
 
 
 
 
 
 

Depreciation
 
 
92
 
 
 
85
 

Amortization of intangibles
 
 
12
 
 
 
15
 

Share-based payments
 
 
41
 
 
 
54
 

Tax benefits from share-based compensation
 
 
1
 
 
 
6
 

Deferred income taxes
 
 
65
 
 
 
(23 
)

Loss on sale of assets
 
 
55
 
 
 
--
 

Unrealized depreciation (appreciation) on trading securities
 
 
(66 
)
 
 
10
 

Other
 
 
6
 
 
 
--
 

Changes in operating assets and liabilities:
 
 
 
 
 
 
 
 

Trade receivables
 
 
(144 
)
 
 
(162 
)

Inventories
 
 
(35 
)
 
 
(22 
)

Other assets
 
 
(2 
)
 
 
18
 

Accounts payable
 
 
18
 
 
 
35
 

Other current liabilities
 
 
31
 
 
 
43
 

Other long term liabilities
 
 
7
 
 
 
17
 

Net cash from operating activities
 
 
1,115
 
 
 
1,072
 
  
 
 
 
 
 
 
 
 

Cash provided by (used in) investing activities:
 
 
 
 
 
 
 
 

Purchases of property, plant and equipment
 
 
(139 
)
 
 
(127 
)

Purchases of intangible assets
 
 
(1 
)
 
 
(28 
)

Purchases of investments
 
 
(657 
)
 
 
(37 
)

Proceeds from sales and maturities of investments
 
 
717
 
 
 
41
 

Other, net
 
 
--
 
 
 
2
 

Net cash from investing activities
 
 
(80 
)
 
 
(149 
)
  
 
 
 
 
 
 
 
 

Cash provided by (used in) financing activities:
 
 
 
 
 
 
 
 

Repayment of short term debt
 
 
(187 
)
 
 
(186 
)

Repayment of long term debt
 
 
(1 
)
 
 
(1 
)

Dividends on common shares
 
 
(1,048 
)
 
 
(750 
)

Acquisition of treasury shares
 
 
(5 
)
 
 
(21 
)

Proceeds from exercise of stock options
 
 
10
 
 
 
94
 

Tax benefits from share-based payment arrangements
 
 
--
 
 
 
38
 

Net cash from financing activities
 
 
(1,231 
)
 
 
(826 
)
  
 
 
 
 
 
 
 
 

Effect of exchange rates on cash and cash equivalents
 
 
7
 
 
 
6
 
  
 
 
 
 
 
 
 
 

Net increase (decrease) in cash and cash equivalents
 
 
(189 
)
 
 
103
 

Cash and cash equivalents, beginning of period
 
 
2,449
 
 
 
2,134
 
  
 
 
 
 
 
 
 
 

Cash and cash equivalents, end of period
 
$
2,260
 
 
$
2,237
 
  
 
 
 
 
 
 
 
 



  

  
  

  

ALCON, INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Financial Measures





  
 

Change
 
 

Foreign
Currency
Change
 
 

Organic
Change
 
  
 
 
 
 
 
 
 
 
 

Emerging market sales
 
 
(8.3
) %
 
 
( 16.4
) %
 
 
8.1
%
  
 
 
 
 
 
 
 
 
 
 
 
 

Travatan® Family of Products
 
 
15.4
%
 
 
( 8.2
) %
 
 
23.6
%
  
 
 
 
 
 
 
 
 
 
 
 
 

Global advanced technology intraocular lens sales
 
 
30.1
%
 
 
( 8.2
) %
 
 
38.3
%


Note: Organic change presents sales growth without the impact of foreign exchange fluctuations and acquisitions. Management believes organic sales change is an important measure of the company’s operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency
prices.  This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.





  
 

EPS Guidance
 

2009 reported
 
$
6.20-6.35
 

2009 restructuring adjustment
 
 
0.05
 

2009 adjusted
 
$
6.25-6.40
 
  
 
 
 
 


Note: Adjusted net earnings and diluted EPS measure the results of the company's operations without certain items that pertained only to the period presented. Management believes these measures are an important measure of the company’s operations because it provides investors with a clearer picture of the core operations of the company.  This
measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.





  

  
  

  

# # #


Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements principally relate to statements regarding the expectations of our management with respect to the future performance of various aspects of our business. These
statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by our forward-looking statements. Words such as "may," "will," "should," "could," "would," "expect," "plan," "anticipate," "believe," "hope," "intend," "estimate," "project," "predict," "potential" and similar expressions are intended to identify forward-looking statements.
These statements reflect the views of our management as of the date of this press release with respect to future events and are based on assumptions and subject to risks and uncertainties and are not intended to give any assurance as to future results. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Factors that might cause future results to differ include, but are not limited to, the following: the development of commercially viable products may take longer
and cost more than expected; changes in reimbursement procedures by third-party payers may affect our sales and profits; a weakening economy could affect demand for our products; competition may lead to worse than expected financial condition and results of operations; currency exchange rate fluctuations may negatively affect our financial condition and results of operations; pending or future litigation may negatively impact our financial condition and results of operations; litigation settlements may adversely
impact our financial condition; the occurrence of excessive property and casualty, general liability or business interruption losses, for which we are self-insured, may adversely impact our financial condition; product recalls or withdrawals may negatively impact our financial condition or results of operations; government regulation or legislation may negatively impact our financial condition or results of operations; changes in tax laws or regulations in the jurisdictions in which we and our subsidiaries are
subject to taxation may adversely impact our financial performance; supply and manufacturing disruptions could negatively impact our financial condition or results of operations. You should read this press release with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities
and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.


For more information, contact:


Doug MacHatton
Vice President, Investor Relations and
Strategic Corporate Communications
(817) 551-8974
doug.machatton@alconlabs.com
John Selzer
Director, Investor Relations
(817) 568-6166
john.selzer@alconlabs.com
Bob Peterson
Manager, Investor Relations
(817) 551-4687
robert.peterson@alconlabs.com


www.alcon.com